Impedimed (ASX:IPD) — Material Events
ASX:IPD · 10 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
ImpediMed Raises A$15.2 Million to Fuel Growth and Cut Costs, Eyes FY28 Cashflow BreakevenMedium
ImpediMed raises A$15.2 million, implements A$5 million cost cuts, targets FY28 cash flow breakeven
4 May 2026
·Capital Raising
·85
ImpediMed Accelerates Growth with 15% Revenue Rise and Platform ExpansionMedium
ImpediMed reports 15% revenue growth, expands SOZO platform, completes $15.3M capital raise
27 Aug 2026
·Annual Report
·85
ImpediMed Posts Record Revenue Amid US Expansion and SOZO Pro LaunchMedium
ImpediMed posts record quarterly revenue, expands US hospital footprint, and launches SOZO Pro
30 Oct 2025
·Quarterly Activity and Cash Flow Report
·80
ImpediMed Advances with $3.9M Revenue and Expanding US Heart Health PushMedium
ImpediMed Q2 FY26: $3.9M Revenue, Strong BCRL Reimbursement Gains, US Heart Health Launch
29 Jan 2026
·Quarterly Activity and Cash Flow Report
·75
ImpediMed's SOZO Platform Gains FDA Clearance for Sarcopenia Risk AssessmentMedium
ImpediMed's SOZO Platform Gains FDA Clearance for Sarcopenia Risk Assessment
19 Aug 2026
·Regulatory Clearance
·75
ImpediMed Advances Cancer Survivorship and Heart Health with $15.3m Capital RaiseMedium
ImpediMed reports Q4 FY26 revenue growth, $15.3 million capital raise, and strategic progress in cancer survivorship and heart health
28 July 2026
·Quarterly Activity and Cash Flow Report
·75
ImpediMed Appoints Erik Anderson as CEO to Accelerate US Commercial GrowthMedium
ImpediMed appoints Erik Anderson as CEO to drive US growth and commercial execution
7 Apr 2026
·Executive Appointment
·75
ImpediMed Raises $2.1 Million in Oversubscribed Share Purchase Plan After $13.2 Million PlacementMedium
ImpediMed completes oversubscribed $2.1 million Share Purchase Plan following $13.2 million placement
10 June 2026
·Capital Raising
·75
ImpediMed Strengthens Leadership and Sales Momentum Amid Strategic GrowthMedium
ImpediMed updates on leadership, sales momentum, and strategic growth initiatives
2 June 2026
·CEO Business Update
·70
ImpediMed Expands US Reimbursement to 94% as New CEO Takes HelmMedium
ImpediMed Q3 FY26 revenue $3.5M, expands US reimbursement, appoints new CEO to drive growth
30 Apr 2026
·Quarterly Activity and Cash Flow Report
·70
No articles in this tier for the last 12 months.
Market Mentions
8
- appeared in market wrap coverage
These are market wrap articles where Impedimed (ASX:IPD) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 35 (24 Aug -> 28 Aug) 2026
29 Aug 2026
Healthcare Wrap - Week 34 (17 Aug -> 21 Aug) 2026
22 Aug 2026
Healthcare Wrap - Week 31 (27 July -> 31 July) 2026
1 Aug 2026
Healthcare Wrap - Week 24 (8 June -> 12 June) 2026
13 June 2026
Healthcare Wrap - Week 23 (1 June -> 5 June) 2026
6 June 2026